Cargando…

A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia

BACKGROUND: We compared the time to discontinuation due to lack of tolerability over 24 weeks in patients suffering from schizophrenia treated with pomaglumetad methionil (LY2140023 monohydrate, the prodrug of metabotropic glutamate 2/3 receptor agonist, LY404039) or standard of care (SOC: olanzapin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adams, David H, Kinon, Bruce J, Baygani, Simin, Millen, Brian A, Velona, Isabella, Kollack-Walker, Sara, Walling, David P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666887/ https://www.ncbi.nlm.nih.gov/pubmed/23694720 http://dx.doi.org/10.1186/1471-244X-13-143

Ejemplares similares

Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison
por: Adams, David H., et al.
Publicado: (2014)

Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with Schizophrenia
por: Nisenbaum, Laura K., et al.
Publicado: (2016)

A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia
por: Downing, AnnCatherine M, et al.
Publicado: (2014)

Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia
por: Ruberg, Stephen J, et al.
Publicado: (2011)

Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy
por: Peng, Xiaomei, et al.
Publicado: (2011)

The heterogeneity of antipsychotic response in the treatment of schizophrenia
por: Case, M., et al.
Publicado: (2011)

Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs
por: Liu-Seifert, Hong, et al.
Publicado: (2005)

A Short-Term, Multicenter, Placebo-Controlled, Randomized Withdrawal Study of a Metabotropic Glutamate 2/3 Receptor Agonist Using an Electronic Patient-Reported Outcome Device in Patients With Schizophrenia
por: Stauffer, Virginia L., et al.
Publicado: (2014)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

New atypical antipsychotics for schizophrenia: iloperidone
por: Caccia, Silvio, et al.
Publicado: (2010)

Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers
por: Kantrowitz, Joshua T., et al.
Publicado: (2020)

Atypical antipsychotics in the treatment of early-onset schizophrenia
por: Hrdlicka, Michal, et al.
Publicado: (2015)

New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression
por: Orzelska-Górka, Jolanta, et al.
Publicado: (2022)

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
por: Faries, Douglas E, et al.
Publicado: (2009)

Predictors of switching antipsychotic medications in the treatment of schizophrenia
por: Nyhuis, Allen W, et al.
Publicado: (2010)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
por: Jeon, Sang Won, et al.
Publicado: (2017)

Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone
por: Liu-Seifert, Hong, et al.
Publicado: (2009)

Asenapine: an atypical antipsychotic with atypical formulations
por: Musselman, Meghan, et al.
Publicado: (2021)

Severity in schizophrenia patients receiving atypical antipsychotic medications
por: Alam Fatmi1j, Syed Meraj, et al.
Publicado: (2022)

Atypical antipsychotics, more than just an antipsychotic
por: Tendilla-Beltrán, Hiram, et al.
Publicado: (2020)

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2005)

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor
por: Yingling, Jonathan M., et al.
Publicado: (2017)

The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial
por: Chen, Lei, et al.
Publicado: (2011)

Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2008)

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2006)

Association of Typical versus Atypical Antipsychotics with Symptoms and Quality of Life in Schizophrenia
por: Fujimaki, Koichiro, et al.
Publicado: (2012)

Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2008)

Neural Basis for the Ability of Atypical Antipsychotic Drugs to Improve Cognition in Schizophrenia
por: Sumiyoshi, Tomiki, et al.
Publicado: (2013)

Minimizing Cardiovascular Adverse Effects of Atypical Antipsychotic Drugs in Patients with Schizophrenia
por: Khasawneh, Fadi T., et al.
Publicado: (2014)

A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics
por: Gilca, Marilena, et al.
Publicado: (2014)

Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia
por: MacEwan, Joanna P., et al.
Publicado: (2016)

Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy
por: Lipkovich, Ilya A, et al.
Publicado: (2009)

Health-related quality of life in patients treated with atypical antipsychotics
por: de Almeida, Juliana L., et al.
Publicado: (2020)

The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
por: Evernden, Christopher, et al.
Publicado: (2021)

Atypical antipsychotics and delirium in critical care
por: Wise, Matt P, et al.
Publicado: (2011)

Constrictive Pericarditis Associated with Atypical Antipsychotics
por: Chen, Kuan-chin Jean, et al.
Publicado: (2012)

Pedal edema associated with atypical antipsychotics
por: Munshi, Santanu, et al.
Publicado: (2016)

Predictors of Effect of Atypical Antipsychotics on Speech
por: Sinha, Preeti, et al.
Publicado: (2015)

Clinical pharmacology of atypical antipsychotics: an update
por: Mauri, M.C., et al.
Publicado: (2014)

Anti-stress Properties of Atypical Antipsychotics
por: Sanson, Alice, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n90u3odderhcvh8o5gspgkfquc